🇺🇸 Idarubicina in United States

22 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Febrile Neutropenia — 3 reports (13.64%)
  2. Hepatitis — 3 reports (13.64%)
  3. Acute Myeloid Leukaemia Recurrent — 2 reports (9.09%)
  4. Anaemia — 2 reports (9.09%)
  5. Cytomegalovirus Infection Reactivation — 2 reports (9.09%)
  6. Device Related Infection — 2 reports (9.09%)
  7. Diarrhoea — 2 reports (9.09%)
  8. Graft Versus Host Disease — 2 reports (9.09%)
  9. Headache — 2 reports (9.09%)
  10. Hepatocellular Injury — 2 reports (9.09%)

Source database →

Idarubicina in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in United States

Frequently asked questions

Is Idarubicina approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Idarubicina in United States?

PETHEMA Foundation is the originator. The local marketing authorisation holder may differ — check the official source linked above.